

Greater Manchester Strategic Clinical Network and Shire Pharmaceuticals Limited

Joint Working Project Executive Summary

The Greater Manchester Strategic Clinical Network (GM SCN) and Shire Pharmaceuticals Limited are engaged in Joint Working to help to develop a standards led approach to delivering ADHD services for children and young people across Greater Manchester (GM). The parties have agreed that the Project should be undertaken in accordance with the principles and guidance relating to joint working between the NHS and the pharmaceutical industry. The primary objective of the Project is to bring benefits to patients and improve patient outcomes through high quality, cost effective treatment and management aligned to agreed standards. The financial commitments of both parties are similar and significant and, in total, will fall in the range of £20,000 – £31,000. It is anticipated that the Project will commence in January 2018 and continue for a period of at least 1 year and will bring benefits to patients, the GM SCN and Shire.

The objective of this Joint Working project is to improve the standards of ADHD services across the boroughs of Greater Manchester.

It is designed to support:

- Patient outcomes
- Reduced waiting times
- More effective assessment and treatment
- Training for relevant medical and none medical practitioners, especially on the use of appropriate objective tests for ADHD including rating scales and diagnostic tools.

It is anticipated that a report on the outcomes from this joint working will be published during 2018 into early 2019.

For further information please contact:

Shire UK - Phil Anderton, phil.anderton@shire.com

GM SCN Katherine McGuirk, Quality Improvement Manager, CYP Mental Health & Wellbeing - ADHD
Greater Manchester Health and Social Care Partnership, 4th Floor, 3 Piccadilly Place, Manchester.
M1 3BN